Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 2Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 81Myeloid 41Lymphoid 16Gastrointestinal 6Plasma cell 5Thoracic 4Genitourinary 4CNS 3Breast 3Tumor-Agnostic 2Dermatologic 2Classical hematology 2Sarcoma 1Head & Neck 1Gynecologic 1

Conditions

Melanoma 2Uveal Melanoma 1Sarcoma 1Neoplasms, Germ Cell and Embryonal 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 37aldesleukin 26Interleukin-2 25Temozolomide 17fludarabine 16fludarabine phosphate 15trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Azacitidine × Dermatologic × Clear all
NCT04729543 2023-12-04

MC2TCR

Erasmus Medical Center

Phase 1/2 Recruiting
20 enrolled
DermatologicHead & Neck

Uveal Melanoma, Head and Neck Neoplasms, Melanoma

NCT04648826 2021-12-17

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
DermatologicGenitourinarySarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡